A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome

Aminah Jatoi, Megan E. Grudem, Travis J. Dockter, Matthew S Block, Jose (J.C.) Villasboas Bisneto, Angelina Tan, Erin Deering, Pashtoon M. Kasi, Aaron Mansfield, Juliana Perez Botero, Scott Heitaka Okuno, Deanne R. Smith, Alan P Fields

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Paclitaxel causes the paclitaxel-induced acute pain (PIAP) syndrome. Based on preclinical data, we hypothesized that the protein kinase C (PKC) iota inhibitor, auranofin (a gold salt used for other pain conditions), palliates this pain. Methods: In a randomized, double-blinded manner, patients who had suffered this syndrome were assigned a one-time dose of auranofin 6 mg orally on day #2 of the chemotherapy cycle (post-paclitaxel) versus placebo. Patients completed the Brief Pain Inventory and a pain diary on days 2 through 8 and at the end of the cycle. The primary endpoint was pain scores, as calculated by area under the curve, in response to “Please rate your pain by circling the one number that best describes your pain at its worse in the last 24 hours.” Results: Thirty patients were enrolled. For the primary endpoint, mean area under the curve of 55 units (standard deviation 19) and 61 units (standard deviation 22) were observed in auranofin-treated and placebo-exposed patients, respectively (p = 0.44). On day 8 and at the end of the cycle, pain scores in auranofin-treated patients were more favorable, although differences were not statistically significant. Conclusions: In the dose schedule studied, auranofin did not palliate the PIAP syndrome, but delayed beneficial trends suggest further study for this indication.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Nov 12 2016

Fingerprint

Auranofin
Acute Pain
Paclitaxel
Pain
Area Under Curve
Placebos
Inhibition (Psychology)
protein kinase C lambda
Gold
Appointments and Schedules
Salts
Drug Therapy
Equipment and Supplies

Keywords

  • Auranofin
  • Myalgias
  • Protein kinase C

ASJC Scopus subject areas

  • Oncology

Cite this

A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. / Jatoi, Aminah; Grudem, Megan E.; Dockter, Travis J.; Block, Matthew S; Villasboas Bisneto, Jose (J.C.); Tan, Angelina; Deering, Erin; Kasi, Pashtoon M.; Mansfield, Aaron; Botero, Juliana Perez; Okuno, Scott Heitaka; Smith, Deanne R.; Fields, Alan P.

In: Supportive Care in Cancer, 12.11.2016, p. 1-6.

Research output: Contribution to journalArticle

@article{6359bc895da941309847376b14174a34,
title = "A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome",
abstract = "Purpose: Paclitaxel causes the paclitaxel-induced acute pain (PIAP) syndrome. Based on preclinical data, we hypothesized that the protein kinase C (PKC) iota inhibitor, auranofin (a gold salt used for other pain conditions), palliates this pain. Methods: In a randomized, double-blinded manner, patients who had suffered this syndrome were assigned a one-time dose of auranofin 6 mg orally on day #2 of the chemotherapy cycle (post-paclitaxel) versus placebo. Patients completed the Brief Pain Inventory and a pain diary on days 2 through 8 and at the end of the cycle. The primary endpoint was pain scores, as calculated by area under the curve, in response to “Please rate your pain by circling the one number that best describes your pain at its worse in the last 24 hours.” Results: Thirty patients were enrolled. For the primary endpoint, mean area under the curve of 55 units (standard deviation 19) and 61 units (standard deviation 22) were observed in auranofin-treated and placebo-exposed patients, respectively (p = 0.44). On day 8 and at the end of the cycle, pain scores in auranofin-treated patients were more favorable, although differences were not statistically significant. Conclusions: In the dose schedule studied, auranofin did not palliate the PIAP syndrome, but delayed beneficial trends suggest further study for this indication.",
keywords = "Auranofin, Myalgias, Protein kinase C",
author = "Aminah Jatoi and Grudem, {Megan E.} and Dockter, {Travis J.} and Block, {Matthew S} and {Villasboas Bisneto}, {Jose (J.C.)} and Angelina Tan and Erin Deering and Kasi, {Pashtoon M.} and Aaron Mansfield and Botero, {Juliana Perez} and Okuno, {Scott Heitaka} and Smith, {Deanne R.} and Fields, {Alan P}",
year = "2016",
month = "11",
day = "12",
doi = "10.1007/s00520-016-3467-9",
language = "English (US)",
pages = "1--6",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome

AU - Jatoi, Aminah

AU - Grudem, Megan E.

AU - Dockter, Travis J.

AU - Block, Matthew S

AU - Villasboas Bisneto, Jose (J.C.)

AU - Tan, Angelina

AU - Deering, Erin

AU - Kasi, Pashtoon M.

AU - Mansfield, Aaron

AU - Botero, Juliana Perez

AU - Okuno, Scott Heitaka

AU - Smith, Deanne R.

AU - Fields, Alan P

PY - 2016/11/12

Y1 - 2016/11/12

N2 - Purpose: Paclitaxel causes the paclitaxel-induced acute pain (PIAP) syndrome. Based on preclinical data, we hypothesized that the protein kinase C (PKC) iota inhibitor, auranofin (a gold salt used for other pain conditions), palliates this pain. Methods: In a randomized, double-blinded manner, patients who had suffered this syndrome were assigned a one-time dose of auranofin 6 mg orally on day #2 of the chemotherapy cycle (post-paclitaxel) versus placebo. Patients completed the Brief Pain Inventory and a pain diary on days 2 through 8 and at the end of the cycle. The primary endpoint was pain scores, as calculated by area under the curve, in response to “Please rate your pain by circling the one number that best describes your pain at its worse in the last 24 hours.” Results: Thirty patients were enrolled. For the primary endpoint, mean area under the curve of 55 units (standard deviation 19) and 61 units (standard deviation 22) were observed in auranofin-treated and placebo-exposed patients, respectively (p = 0.44). On day 8 and at the end of the cycle, pain scores in auranofin-treated patients were more favorable, although differences were not statistically significant. Conclusions: In the dose schedule studied, auranofin did not palliate the PIAP syndrome, but delayed beneficial trends suggest further study for this indication.

AB - Purpose: Paclitaxel causes the paclitaxel-induced acute pain (PIAP) syndrome. Based on preclinical data, we hypothesized that the protein kinase C (PKC) iota inhibitor, auranofin (a gold salt used for other pain conditions), palliates this pain. Methods: In a randomized, double-blinded manner, patients who had suffered this syndrome were assigned a one-time dose of auranofin 6 mg orally on day #2 of the chemotherapy cycle (post-paclitaxel) versus placebo. Patients completed the Brief Pain Inventory and a pain diary on days 2 through 8 and at the end of the cycle. The primary endpoint was pain scores, as calculated by area under the curve, in response to “Please rate your pain by circling the one number that best describes your pain at its worse in the last 24 hours.” Results: Thirty patients were enrolled. For the primary endpoint, mean area under the curve of 55 units (standard deviation 19) and 61 units (standard deviation 22) were observed in auranofin-treated and placebo-exposed patients, respectively (p = 0.44). On day 8 and at the end of the cycle, pain scores in auranofin-treated patients were more favorable, although differences were not statistically significant. Conclusions: In the dose schedule studied, auranofin did not palliate the PIAP syndrome, but delayed beneficial trends suggest further study for this indication.

KW - Auranofin

KW - Myalgias

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=84994691896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994691896&partnerID=8YFLogxK

U2 - 10.1007/s00520-016-3467-9

DO - 10.1007/s00520-016-3467-9

M3 - Article

SP - 1

EP - 6

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -